PAVmed (PAVM) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
24 Feb, 2026Executive summary
Special Meeting scheduled for March 27, 2026, to vote on four key proposals impacting capital structure, governance, and compensation.
Proposals include approval of stock issuance related to a $30M private placement, a charter amendment for director removal, an equity plan increase, and potential adjournment.
The Board unanimously recommends voting in favor of all proposals, citing benefits to capital structure, governance, and employee retention.
Voting matters and shareholder proposals
Stockholders will vote on: (1) Stock Issuance Proposal, (2) Charter Amendment Proposal, (3) Equity Plan Proposal, and (4) Adjournment Proposal.
The Stock Issuance Proposal seeks approval for issuing common stock upon conversion of Series D Preferred Stock and a new convertible note, exceeding 20% of outstanding shares.
The Charter Amendment Proposal allows removal of directors with or without cause by majority vote, while retaining a classified board.
The Equity Plan Proposal increases shares available under the 2014 Long-Term Incentive Equity Plan by 1,500,000 shares.
The Adjournment Proposal allows the meeting to be adjourned if insufficient votes are present.
Board of directors and corporate governance
Board remains classified in three classes, but amendment would allow removal of directors without cause by majority vote.
Holders of Series D Preferred Stock retain the right to appoint one director as long as at least 10,000 shares are outstanding.
Advance notice and disclosure requirements for shareholder proposals and director nominations remain in place.
Latest events from PAVmed
- 2025 saw a sharp revenue drop, a net loss, and major recapitalization efforts amid going concern risks.PAVM
Q4 202527 Mar 2026 - Record test growth and revenue surge, but losses and funding risks persist.PAVM
Q2 202426 Mar 2026 - Q1 2025 net income reached $17.7M as Lucid and Veris advanced, but going concern risks persist.PAVM
Q1 202526 Mar 2026 - Stabilized finances, advanced diagnostics, and expanded digital health amid ongoing capital needs.PAVM
Q3 202526 Mar 2026 - Q2 2025 featured 2,756 EsoGuard tests, $1.2M revenue, and strengthened liquidity.PAVM
Q2 202526 Mar 2026 - Proxy seeks approval for stock issuance, charter amendment, and expanded equity plan.PAVM
Proxy Filing13 Feb 2026 - Record Q3 revenue and Lucid deconsolidation boost net income, but liquidity risks persist.PAVM
Q3 202414 Jan 2026 - Record test growth, profitability, and new financing drive future momentum.PAVM
Q4 202426 Dec 2025 - Shelf registration enables up to $125M in securities sales to fund healthcare technology expansion.PAVM
Registration Filing16 Dec 2025